Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. Defence Therapeutics Inc.
  6. News
  7. Summary
    DTC   CA24463V1013

DEFENCE THERAPEUTICS INC.

(DTC)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE : Defence Therapeutics Inc.: DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

10/13/2021 | 02:31am EST

DGAP-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous Defence Therapeutics Inc.: DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER 2021-10-13 / 08:30 The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE

DEFENCE THERAPEUTICS ACCUM^TM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

Vancouver, BC, Canada, October 13^th, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce strong in vitro results of its Accum^TM variants on the recent Enhertu(R) (fam-trastuzumab-deruxtecan-nxki) ADC owned by AstraZeneca and Daiichi Sankyo.

Defence has successfully selected and tested 5 Accum^TM variants to the T-deruxtecan ADC Therapeutic. The 5 selected Accum-T-deruxtecan increases the potency of T-deruxtecan ADC Therapeutic by approximatively 5-fold on the HER2 positive breast cancer Trastuzumab and T-DM1 resistant cell line model named JIMT-1. At concentration of 0.001 ug/ml, T-deruxtecan only induce approximatively 13% of cytotoxicity comparatively to the 5 Accum-T-deruxtecan variants that increase the cytotoxicity by 21-37%. The 5 selected Accum^TM variants will be sent to our collaborator at the HUS Comprehensive Cancer Center in Helsinki, Finland for the optimization of Defence's Accum-T-deruxtecan ADC Therapeutic. Defence's Accum^TM platform has been developed and tested in vitro to enhance the intracellular drug delivery on multiple ADCs that are FDA approved or under development. The Accum^TM technology platform is very efficient at enhancing intracellular delivery of proteins of pharmacological interests such as ADCs or vaccine antigens. "The strong results confirmed the expectation of our scientific team that the Accum^TM can increase the routing and delivery of the T-deruxtecan to the nucleus and consequently increased more significantly the potency of the ADC. That confirms also and again the strength and optimization of our Accum^TM platform in the ADC field of therapeutics against cancer and the solid competitive advantage we have with our Accum^TM variants derived from our Accum^TM technology platform", says Mr. Sebastien Plouffe, CEO of Defence Therapeutics. According to Facts and Factors market research report, the Global Breast Cancer Treatment Market size & share revenue is expected to grow from USD 19.24 Billion in 2019 to reach USD 34.06 Billion by 2026, at 8.5% annual CAGR growth during forecast period of 2021-2026. About Defence: Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM^TM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

For further information: Sebastien Plouffe, President, CEO and Director P: (514) 947-2272 Splouffe@defencetherapeutics.com www.defencetherapeutics.com Cautionary Statement Regarding "Forward-Looking" Information This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

-----------------------------------------------------------------------------------------------------------------------

2021-10-13 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

-----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      Defence Therapeutics Inc. 
              1680 - 200 Burrard St 
              V6C3L6 Vancouver 
              Canada 
E-mail:       info@defencetherapeutics.com 
Internet:     https://defencetherapeutics.com 
ISIN:         CA24463V1013 
WKN:          A3CN14 
Listed:       Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto 
EQS News ID:  1240336 
 
End of News   DGAP News Service 
=------------ 

1240336 2021-10-13

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1240336&application_name=news

(END) Dow Jones Newswires

October 13, 2021 02:30 ET (06:30 GMT)

All news about DEFENCE THERAPEUTICS INC.
11/30Defence therapeutics vaccines and program development
EQ
11/23Defence therapeutics cancer vaccine accuvac-d001 manufacturing targets melanoma and bre..
EQ
11/09Defence therapeutics appoints dr. riam shammaa to its board of directors
EQ
11/09Defence Therapeutics Inc. Appoints Riam Shammaa to its Board of Directors
CI
11/03VACCINE RESULTS : Defence therapeutics reports successful completion of its covid-19 vacci..
EQ
11/03Defence Therapeutics Inc. Reports Successful Completion of its COVID-19 Vaccine AccuVAC..
CI
10/19Defence Therapeutics Scores Again With New Planned Phase 1 Trial Evaluating Its DC Canc..
AQ
10/13Defence Therapeutics Accumtm Variants in Vitro Study Increases the Potency of T-Deruxte..
CI
10/13DEFENCE THERAPEUTICS INC. : Defence therapeutics accumtm variants in vitro study increases..
EQ
10/12DEFENCE THERAPEUTICS ACCUM(TM) TECHN : Dtcff)
AQ
More news
Financials
Sales 2021 - - -
Net income 2021 -2,86 M -2,22 M -2,22 M
Net cash 2021 5,45 M 4,24 M 4,24 M
P/E ratio 2021 -65,6x
Yield 2021 -
Capitalization 209 M 163 M 163 M
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees -
Free-Float 93,9%
Chart DEFENCE THERAPEUTICS INC.
Duration : Period :
Defence Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
SÚbastien Plouffe President, Chief Executive Officer & Director
P. Joseph Meagher Chief Financial Officer & Director
Raimar L÷benberg Chairman
Simon Beaudoin Chief Technology & Science Officer
Moutih Rafei Director & VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
DEFENCE THERAPEUTICS INC.0.00%163
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298